Intended for healthcare professionals


Type 1 diabetes: US approves drug that can delay onset

BMJ 2022; 379 doi: (Published 18 November 2022) Cite this as: BMJ 2022;379:o2798
  1. Gareth Iacobucci
  1. The BMJ

US regulators have approved an immunotherapy treatment for type 1 diabetes that can delay the onset of the condition by up to three years.1 The Food and Drug Administration approved Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older who currently have stage 2 type 1 diabetes.

The drug, delivered by intravenous injection once a day for 14 consecutive days, has been shown to delay the onset of type 1 diabetes by an average of three years in people at high risk of developing the condition. The approval means it can now be prescribed in the US to people at …

View Full Text

Log in

Log in through your institution


* For online subscription